Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

Exploring treatments for central sleep apnea

Official title: Central Sleep Apnea: Physiologic Mechanisms to Inform Treatment

Run by VA Office of Research and Development · NCT04118387 · Data updated 2026-11-12

This study is testing new combination treatments for central sleep apnea in veterans to see if they can help improve breathing and quality of life.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment200 (estimated)
SponsorVA Office of Research and Development
Federal
Locations1 site (Detroit, Michigan)
StatusRecruiting
StartedJanuary 7, 2021
Main results expectedDecember 31, 2026
Study endsJune 30, 2027
Registry record updatedJuly 20, 2026
Trial IDNCT04118387 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are men and women veterans diagnosed with central sleep apnea, specifically those with an Apnea Hypopnea Index greater than 15 per hour.

Probably not a fit

Patients who are under 18 years old, pregnant, or have severe respiratory diseases requiring oxygen therapy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the physiological mechanisms underlying central sleep apnea (CSA) to inform future treatment strategies. It focuses on testing combination therapies, including positive airway pressure (PAP) alongside pharmacological agents like acetazolamide and zolpidem, in veterans with CSA. The goal is to identify effective multi-modality therapies that can normalize respiration and improve the quality of life for patients suffering from this condition. The study aims to provide insights that could guide future clinical trials and enhance care for individuals with CSA.

Why it matters

Potential benefit: If successful, this study could lead to more effective treatment options for patients with central sleep apnea, improving their overall health and quality of life.

How similar studies have gone: While the approach of using combination therapies for CSA is being explored, the specific combination of treatments in this study is novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Men and women Veterans with central sleep apnea, defined as Apnea Hypopnea Index (AHI)\>15/hour with CAHI\>5/hour, will be included in the experiments

Exclusion Criteria:

* less than 18 years old
* pregnant or breastfeeding female
* have severe respiratory disease that require to be on oxygen
* recent health event that may affect the ability to participate in the study,
* Body Mass Index (BMI) is \>40 kg/m2
* significant insomnia
* mental instability
* recent health event that may affect sleep
* if at any time the principal investigator (PI) identifies that a certain drug is not suitable, or are unable to use the device that is used to treat sleep apnea, will be not be allowed to participate in the study

Where it's running

  • John D. Dingell VA Medical Center, Detroit, MI
    Detroit, Michigan, United States
    Recruiting

Study contacts

  • Principal investigator: M Safwan Badr, MD — John D. Dingell VA Medical Center, Detroit, MI
  • Study coordinator: M S Badr, MD
  • Email: sbadr@med.wayne.edu
  • Phone: (313) 576-1000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.